XSHG
600211
Market cap1.74bUSD
Oct 09, Last price
36.78CNY
1D
1.71%
1Q
-3.29%
Jan 2017
-4.89%
Name
Tibet Rhodiola Pharmaceutical Holding Co
Chart & performance
P/E
12.64
P/S
4.02
EPS
2.91
Div yield, %
5.17%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
16.53%
Revenues
2.95b
+5.13%
Net income
938m
-10.78%
CFO
1.03b
+3.21%
Dividend
Sep 15, 20261.146 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products. In addition, the company offers biopharmaceuticals, traditional Chinese medicine, and chemical drugs for various fields, such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines. The company was founded in 1999 and is headquartered in Lhasa, China.
Key people
Yuandong Guo
General Manager · since 2014
Chunyan Yang
Deputy General Manager · since 2009
Lan Liu
Secretary of the Board · since 2010
Dabin Chen
Chairman of the Board · since 2015
Hui Peng
Director · since 2011
Chunhua Zhao
Director · since 2011
Yucheng Zhou
Vice Chairman of the Board · since 2015
Wenxing Li
Independent Director · since 2011
Xianglin Sima
Independent Director · since 2007
Independent Director · since 2007
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||